SCHEMBL6434174

SCHEMBL6434174

CC(C)(NS(=O)(=O)c1ccc2c(N(Cl)C(=N)N)cncc2c1)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
PLAU P00749 9/20 0.50
PLG P00747 4/20 0.50
PLAT P00750 2/20 0.50
CYP4F2 P78329 1/20 0.34
CYP4A11 Q02928 1/20 0.34
THRB P10828 1/20 0.32
SCN9A Q15858 4/20 0.32
ADAM17 P78536 1/20 0.31
SLC16A3 O15427 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6437764 0.99 PLAU (0.49) PLAUPLGPLATCYP4F2CYP4A11
Hydrochloric Acid SCHEMBL7372713 0.92 PLAU (0.41) PLAUPLGPLATTHRBSCN9A
SCHEMBL7362083 0.90 PLAU (0.40) PLAUPLGPLATTHRBSCN9A
Hydrochloric Acid SCHEMBL6433670 0.85 PLAU (0.51) PLAUPLGPLATCYP4F2CYP4A11
SCHEMBL7373625 0.81 MEN1 (0.31) PLAU
Trifluoroacetic Acid SCHEMBL7365054 0.81 PLAU (0.45) PLAUPLGPLAT
Hydrochloric Acid SCHEMBL7376136 0.81 PLAU (0.48) PLAUPLGPLAT
Trifluoroacetic Acid SCHEMBL7369183 0.81 PLAU (0.43) PLAU
SCHEMBL6965041 0.80 F2 (0.35) PLAUPLGPLATSCN9A
Trifluoroacetic Acid SCHEMBL7456725 0.80 PLG (0.47) PLAUPLGPLAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030099693-A1 Wafer PFIZER INC. 2003-05-29 US claimed
WO-2003037395-A1 WAFER FOR WOUNDS PFIZER LIMITED (GB) 2003-05-08 WO claimed
EP-1077945-B1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER (US) 2003-01-08 EP claimed
US-20050026836-A1 Composition for the treatment of damaged tissue DACK KEVIN NEIL (GB) 2005-02-03 US disclosed
US-20030199440-A1 Composition for the treatment of damaged tissue PFIZER INC. 2003-10-23 US disclosed
US-20030099693-A1 Wafer PFIZER INC. 2003-05-29 US disclosed
WO-2003037395-A1 WAFER FOR WOUNDS PFIZER LIMITED (GB) 2003-05-08 WO disclosed
EP-1242120-A2 COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE Pfizer Limited (GB) 2002-09-25 EP disclosed
WO-2001049309-A2 COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE PFIZER LIMITED (GB) 2001-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199440-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 PLAU 119/4885PLG 33/4885PLAT 48/4885
US-20050026836-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 PLAU 119/4885PLG 33/4885PLAT 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.